^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AlloStim (bioengineered allogeneic immune cells)

    i
    Other names: bioengineered allogeneic immune cells, T-Stim cells
    Associations

    News

    Trials
    Company:
    Immunovative
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=24, Recruiting, Immunovative Therapies, Ltd. | Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    2ms
    ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov)
    P2/3, N=150, Recruiting, Immunovative Therapies, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    sorafenib • 5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • AlloStim (bioengineered allogeneic immune cells)
    1year
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Recruiting, Immunovative Therapies, Ltd. | Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    over1year
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Recruiting, Immunovative Therapies, Ltd. | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    AlloStim (bioengineered allogeneic immune cells)
    almost3years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Recruiting, Immunovative Therapies, Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    3years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Not yet recruiting, Immunovative Therapies, Ltd. | Trial primary completion date: Sep 2022 --> Dec 2022
    Clinical • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    over3years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Not yet recruiting, Immunovative Therapies, Ltd. | Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Sep 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    over3years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Not yet recruiting, Immunovative Therapies, Ltd. | Initiation date: Oct 2020 --> Jan 2021
    Clinical • Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    almost4years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Not yet recruiting, Immunovative Therapies, Ltd. | Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2021
    Clinical • Trial initiation date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    almost4years
    STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2b, N=24, Not yet recruiting, Immunovative Therapies, Ltd.
    Clinical • New P2b trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    AlloStim (bioengineered allogeneic immune cells)
    over4years
    AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=0, Withdrawn, Immunovative Therapies, Ltd. | N=450 --> 0 | Not yet recruiting --> Withdrawn
    Clinical • Enrollment change • Trial withdrawal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • BRAF mutation
    |
    Erbitux (cetuximab) • AlloStim (bioengineered allogeneic immune cells)
    over4years
    AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2a, N=12, Completed, Immunovative Therapies, Ltd. | Recruiting --> Completed | Phase classification: P2 --> P2a | N=18 --> 12
    Clinical • Trial completion • Phase classification • Enrollment change • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    AlloStim (bioengineered allogeneic immune cells)